Merus BV Current Deferred Revenue Over Time
MRUS Stock | USD 45.49 1.13 2.55% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Merus BV Performance and Merus BV Correlation. Merus |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Merus BV. If investors know Merus will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Merus BV listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (4.03) | Revenue Per Share 0.584 | Quarterly Revenue Growth 0.067 | Return On Assets (0.22) | Return On Equity (0.45) |
The market value of Merus BV is measured differently than its book value, which is the value of Merus that is recorded on the company's balance sheet. Investors also form their own opinion of Merus BV's value that differs from its market value or its book value, called intrinsic value, which is Merus BV's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Merus BV's market value can be influenced by many factors that don't directly affect Merus BV's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Merus BV's value and its price as these two are different measures arrived at by different means. Investors typically determine if Merus BV is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Merus BV's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities Current Deferred Revenue Analysis
Compare Merus BV and related stocks such as Anebulo Pharmaceuticals, Adagene, and Acrivon Therapeutics, Current Deferred Revenue Over Time
Select Fundamental2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
ADAG | 33 K | 33 K | 33 K | 33 K | 33 K | 33 K | 33 K | 33 K | 33 K | 993.4 K | 725.5 K | 5.5 M | 15.1 M | 52.9 K | 50.2 K |
ACRV | 66 K | 66 K | 66 K | 66 K | 66 K | 66 K | 66 K | 66 K | 66 K | 66 K | 66 K | 66 K | 69 K | 79.3 K | 74.2 K |
ANAB | 1.3 M | 1.3 M | 1.3 M | 1.3 M | 10.1 M | 2.9 M | 3.4 M | 4.9 M | 8.7 M | 10.2 M | 10.2 M | 10.2 M | 10.2 M | 11.7 M | 6.5 M |
CRNX | (724 K) | (724 K) | (724 K) | (724 K) | (724 K) | (724 K) | (724 K) | (724 K) | (724 K) | (724 K) | (835 K) | (939 K) | 2.2 M | 2.1 M | 2.2 M |
INBX | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 2.6 M | 1.6 M | 7.9 M | 3.1 M | 2 M | 166 K | 149.4 K | 141.9 K |
LYEL | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 4.5 M | 6.1 M | 5 M | 21.9 M | 20.4 M | 12.7 M |
KRON | 9 K | 9 K | 9 K | 9 K | 9 K | 9 K | 9 K | 9 K | 9 K | 818 K | 5 M | 9.1 M | 9.1 M | 9.6 M | 6.1 M |
PTGX | 31.8 M | 31.8 M | 31.8 M | 31.8 M | 31.8 M | 31.8 M | 31.8 M | 31.8 M | 8.2 M | 41.5 M | 14.5 M | 1.6 M | 69 K | 3 K | 2.9 K |
REPL | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 4.9 M | 8.2 M | 12.1 M | 21.7 M | 30.7 M | 17.1 M |
LRMR | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.9 M) | (2.6 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (5.5 M) | (4.9 M) | (5.2 M) |
SNDX | 2.4 M | 2.4 M | 2.4 M | 3.4 M | 3.4 M | 1.2 M | 1.2 M | 1.6 M | 1.5 M | 1.5 M | 1.5 M | 12.8 M | 39 M | 44.8 M | 47.1 M |
STRO | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 43.6 M | 10.7 M | 21.6 M | 19.5 M | 14.6 M | 5.5 M | 106.6 M | 20.7 M | 33.4 M |
Merus BV and related stocks such as Anebulo Pharmaceuticals, Adagene, and Acrivon Therapeutics, Current Deferred Revenue description
Revenue that has been collected but not yet earned, typically from prepaid service contracts or subscriptions. This amount is considered a liability until the service is provided or the subscription period ends.My Equities
My Current Equities and Potential Positions
Merus BV | MRUS |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
Location | Netherlands |
Exchange | NASDAQ Exchange |
USD 45.49
Additional Tools for Merus Stock Analysis
When running Merus BV's price analysis, check to measure Merus BV's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Merus BV is operating at the current time. Most of Merus BV's value examination focuses on studying past and present price action to predict the probability of Merus BV's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Merus BV's price. Additionally, you may evaluate how the addition of Merus BV to your portfolios can decrease your overall portfolio volatility.